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ABSTRACT
This study was designed to characterize the b-lactamase content of carbapenem-resistant Pseudomonas
aeruginosa isolates recovered during 2006 and 2007 in a large tertiary-care centre in Nairobi, Kenya.
Molecular characterization was done using PCR and sequencing, and typing was performed using
pulsed-field gel electrophoresis (PFGE). In total, 416 P. aeruginosa isolates were obtained during that
period, of which 57 (13.7%) were resistant to carbapenems. All carbapenem-resistant isolates tested
positive for metallo-b-lactamase (MBL) production. All MBL isolates produced VIM-2 with two types of
integron structures. PFGE identified three clonally related groups of VIM-2-producing P. aeruginosa,
including a pan-resistant clone that was responsible for nosocomial outbreaks during 2006 and 2007 in
the intensive-care unit. These findings suggest that continuous molecular surveillance needs to be
performed to monitor the spread within the hospital of this pan-resistant strain. This study is the first
report of VIM-2-producing P. aeruginosa from the African continent.
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INTRODUCTION
Pseudomonas aeruginosa isolates producing metallo-
b-lactamases (MBLs) were first reported from
Japan in 1991, and since then have been described
from various parts of the world, including Asia,
Europe, Australia, South America and North
America. [1] MBLs are binuclear zinc-dependent
enzymes and are susceptible to inhibition by metal
chelators such as EDTA. These enzymes have the
ability to hydrolyze a wide variety of b-lactam
agents such as penicillins, cephalosporins and
carbapenems, but not the monobactams.
The genes responsible for the production of
MBLs are typically part of an integron structure
and are encoded on large transferable plasmids
[2]. Therefore, P. aeruginosa isolates producing
MBLs are often resistant to different groups of
antimicrobial agents, and this resistance can be
transferred to various types of bacteria. Acquired
MBLs can be divided into six categories according
to their molecular structure, namely the IMP,
VIM, GIM, SIM and SPM types [1] and, more
recently, AIM [3].
MBL-producing P. aeruginosa isolates have
been responsible for several nosocomial outbreaks
in tertiary centres from different parts of the
world, illustrating the need for proper infection
control practices [4]. These isolates have also been
responsible for serious infections such as septi-
caemia and pneumonia, and have been associated
with failure of therapy with carbapenems [5].
The Division of Microbiology at the Aga Khan
University Hospital in Nairobi, Kenya noted the
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appearance of multiresistant P. aeruginosa in the
intensive-care unit (ICU) during 2005. These
isolates were resistant to the cephalosporins,
carbapenems, aminoglycosides and fluoroquino-
lones. As MBL-producing Pseudomonas spp. have
not previously been described from the African
continent, a study was designed to determine
whether MBLs were present among these isolates
and to investigate the prevalence of these
enzymes among clinical isolates of carbapenem-
intermediate or carbapenem-resistant (CR)
P. aeruginosa from the Aga Khan University
Hospital during 2006–2007.
MATERIALS AND METHODS
Aga Khan University Hospital
Established in 1958, the Aga Khan University Hospital,
Nairobi is a 254-bed long-term care facility that provides
general medical services, specialist clinics and high-technology
diagnostic services. The hospital serves as a referral centre for
specialized medical care and diagnostic services from various
hospitals and clinics within the region.
Bacterial isolates
Consecutive non-duplicate isolates of P. aeruginosa that were
intermediate or resistant (non-susceptible) to either imipenem
(MIC >8 mg ⁄ L) or meropenem (MIC >8 mg ⁄ L) (referred to as
CR), collected at the Division of Microbiology, from the Aga
Khan University Hospital during January 2006 to June 2007
were included in this study. Isolates were identified to the
species level with Vitek (Vitek AMS; bioMe´rieux Vitek Systems
Inc., Hazelwood, MO, USA).
Antimicrobial susceptibility testing
MICs of the following drugs were initially determined by
Vitek 2 (Vitek AMS; bioMe´rieux Vitek Systems Inc.), and
microdilution panels were performed on all MBL-positive
isolates (Microscan Gram negative NMIC30; Dade Behring
Canada Inc., Mississauga, ON, Canada); piperacillin,
ceftazidime, cefepime, aztreonam, imipenem, meropenem,
ciprofloxacin, gentamicin, amikacin and tobramycin. Colistin
susceptibility was determined using the Etest (AB BioDisk,
Solna, Sweden). The quality control strains used for this part of
the study were Escherichia coli ATCC 25922 and P. aeruginosa
ATCC 27853. Throughout this study, results were interpreted
using CLSI criteria for broth dilution [6].
Identification of MBLs
The presence of MBLs was evaluated in the clinical isolates of
CR P. aeruginosa using both an EDTA screen test [7] and the
MBL Etest (AB BioDisk) according to the manufacturer’s
instructions. DNA template preparation and duplex PCR
amplification for the simultaneous detection of the blaIMP and
blaVIM b-lactamase genes were carried out on a Thermal
Cycler 9700 instrument (Applied Bio-systems, Foster City, CA,
USA) with primers and conditions as previously described [7].
Sequencing of the VIM genes was performed using the class 1
integron primers 5CS (5¢-GGC ATC CAA GCA GCA AG-3¢)
and 3CS (5¢-AAG CAG ACT TGA CCT GA-3¢) in
combination with IMP and VIM primers, respectively. Two
different amplicons per isolate were sequenced in an overlap-
ping fashion to ensure that the entire MBL allele was obtained.
Automated sequencing was performed on the PCR products
with the ABI Prism 3100 Genetic Analyzer (Applied Bio-
systems, Norwalk, CT, USA) as previously described, using
the EQUENCE NALYSIS software. [8] The 3CS extremity of the
integron was specifically targeted using the VIM-2-specific
forward primer [7], with the 402-TniC-B reverse primer
(5¢-ACGTGCCGGTAGAGCGTCTG-3¢) [9].
Pulsed-field gel electrophoresis (PFGE)
PFGE was performed on selected MBL-producing isolates,
using a protocol previously described [8]. Gel images in tiff
format were exported to BIONUMERICS software version 3.5
(Applied Maths, Sint-Martens-Latem, Belgium) for analysis.
Comparisons for P. aeruginosa were made using the band-
based Dice coefficient, which is a binary coefficient measuring
similarity, based upon common and different bands. Dendro-
grams were generated using the unweighted pair group
method using arithmetic averages (UPGMA) with 1.5%
position tolerance. DNA relatedness was calculated, on the
basis of the Dice coefficient, and isolates were considered to be
genetically related if the Dice coefficient correlation was 80%
or greater, which corresponds to the ‘possibly related (four to
six bands difference)’ criteria of Tenover et al.[10].
RESULTS
Bacterial isolates
During the 18-month study period, 416 P. aeru-
ginosa isolates were obtained at Aga Khan Uni-
versity Hospital, of which 57 (13.7%) were
resistant to the carbapenems: three (5%) were
isolated from urine, four (7%) from blood, 17
(30%) from wounds (purulent), 30 (53%) from
respiratory tract specimens, and the remaining
three (5%) from various other specimens. The
majority of CR isolates (33 ⁄ 57 (58%)) originated
from the ICU.
Antimicrobial susceptibility
The 57 clinical isolates included in this study were
highly resistant to imipenem and meropenem
(MICs, >256 and >32 mg ⁄ L respectively) and 30
(53%) were resistant to piperacillin and aztreo-
nam, whereas 57 (100%) were resistant to ceftaz-
idime, cefepime, tobramycin, gentamicin,
amikacin and ciprofloxacin. No colistin resistance
was detected, although 12 isolates had an MIC of
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2 mg ⁄ L (i.e. the CLSI breakpoint for colistin).
Paterson recently suggested definitions for multi-
drug-resistant and pan-resistant P. aeruginosa [11];
all the isolates were multidrug-resistant and 53%
were pan-resistant.
Identification of MBLs and cassette arrays
All of the CR P. aeruginosa isolates were MBL-
positive according to both phenotypic methods,
and PCR identified blaVIM genes in all of them.
Among the 57 isolates, 15 isolates were randomly
selected for additional molecular characterization.
These included 11 isolates from the ICU, three
from general wards, and one from an outpatient.
PCR with primers 5CS and 3CS, combined with
VIM primers, amplified various amplicons, rang-
ing from 600 bp to 1.2 kb. Sequence analysis of
the products obtained with the VIM primers
revealed 100% identity with the sequence of the
blaVIM-2 allele in all the isolates [12]. Although five
of the 15 isolates possessed blaVIM-2 as a single
cassette, the other ten blaVIM-2-positive isolates
carried two gene cassettes, consisting of blaVIM-2
preceded by an aacA4 gene cassette (encoding the
aminoglycoside acetyltransferase AAC(6¢)-Ib).
PCR with the remaining 42 isolates showed that
the majority (29 ⁄ 42) possessed blaVIM-2 as a single
cassette, whereas the other 13 blaVIM-2-positive
isolates carried two gene cassettes, consisting of
blaVIM-2 preceded by an aacA4 gene cassette.
However, the 3CS extremity of the blaVIM-2-con-
taining integron was not amplified, probably
suggesting a Tn402-like structure, as recently
identified in a French blaVIM-2-positive isolate at
the origin of an outbreak [9]. PCR with primers
specific for the TniC of Tn402 was negative as
well. The primer combination consisted of the
VIM-2-specific forward primer and the
402-TniC-B reverse primer (5¢-ACGTGCCGGTA
GAGCGTCTG-3¢). The positive control used dur-
ing this part of the experiment was strain 29 [9].
A PFGE analysis was performed as described
previously [13], followed by an I-CeuI digestion
and a Southern blot hybridization analysis [12] for
the determination of the precise genetic location
of the blaVIM-2 genes in AFC-03, AFC-01 and AFC-
08. Chromosomal DNAs from VIM-2-positive
P. aeruginosa isolate COL-1 were included as a
positive control [12]. The membrane was succes-
sively hybridized with probes for blaVIM-2 and 16S
and 23S rRNA genes, as described previously,
thus demonstrating the chromosomal location of
blaVIM-2 (data not shown). Attempts to transfer the
b-lactam resistance marker into E. coli DH10B and
P. aeruginosa AFC-03 by electroporation failed.
PFGE
PFGE identified three closely related groups
of VIM-2-producing P. aeruginosa among the 15
isolates, designated clusters MBLA (n = 6),
MBLAR (n = 2) (i.e. related to A), and a separate
cluster designated MBLB (n = 7) (Fig. 1). The
MBLA, MBLAR and MBLB isolates formed
separate clusters, within which there was >80%
similarity of the PFGE profiles (Fig. 1). The
MBLAR isolates exhibited profiles with >70%
similarity to MBLA, which indicates that MBLA
and MBLAR are related, although the significance
is unknown. Among the 11 isolates from the ICU,
two belonged to cluster MBLA, two to cluster
MBLAR and seven to cluster MBLB; the remaining
four from general wards and the outpatient isolate
belonged to cluster MBLA. It is noteworthy that all
the isolates belonging to cluster MBLB were pan-
resistant (being sensitive only to colistin), whereas
those from clusters MBLA and MBLAR were
multiresistant, being sensitive to piperacillin, azt-
reonam and colistin. Analysis of blaVIM-2 showed
that two of six strains from cluster MBLA, and one
of two from clusters MBLAR and MBLB (n = 7),
consisted of blaVIM-2 preceded by an aacA4 gene
cassette, whereas the remaining strains from clus-
ters MBLA and MBLAR possessed blaVIM-2 as a
single cassette.
DISCUSSION
VIM-4-producing Klebsiella pneumoniae strains
have been previously described from Tunisia
[14], but to our knowledge this is the first report
of VIM-2-producing P. aeruginosa from the Afri-
can continent.
Several surveys have been undertaken regard-
ing the prevalence of MBL-producing isolates
among CR P. aeruginosa, and varying percentages
have been reported worldwide, ranging from 10%
in Turkey [15] to up to 36% in Southeast Asia. [16]
Our results are interesting in that this is the first
study to show that 100% of the CR P. aeruginosa
isolates from the Aga Khan University Hospital
were MBL producers. It seems that other mecha-
nisms of resistance to the carbapenems, such as
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impermeability, which arises via the loss of the
OprD porin [17], or the upregulation of an active
efflux pump system present in the cytoplasmic
membrane of these organisms [18], were absent at
this tertiary-care centre in Nairobi.
Molecular typing of VIM-2-producing P. aeru-
ginosa showed that clonally related strains (the
pan-resistant cluster MBLB with gene cassettes
blaVIM-2 preceded by aacA4) were mostly present
in the ICU and were responsible for nosocomial
outbreaks in this unit during 2006 and 2007
(R. Revathi, unpublished data). Pan-resistant
clusters of VIM-2-producing P. aeruginosa have
also recently been described in Spain [19] and
Korea [20]. Nearly half of the P. aeruginosa isolates
from the ICU collected during the study period
were MBL producers (33 ⁄ 67 (49%)); 21 of these
(64%) were pan-resistant and belonged to cluster
MBLB. Fifteen of the 33 (45%) MBL producers
were isolated from respiratory secretions of septic
patients, and 10 ⁄ 15 (67%) died as a result of the
infection. According to the clinical data obtained
from Kenya, these infected patients received
antibiotic regimens combining piperacillin and
amikacin, ceftazidime and amikacin, ciprofloxacin
and amikacin, or ceftazidime and ciprofloxacin
(colistin was not available in Kenya). This study
supports data from Brazil that showed high
mortality rates resulting from infections due to
MBL-producing P. aeruginosa [21], especially in
patients with ventilator-associated pneumonia
[22]. This suggests that empirical therapy for
suspected P. aeruginosa infections such as
ventilator-associated pneumonia in the ICU of
Aga Kahn University Hospital should include
colistin.
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Fig. 1. Pulsed-field gel electrophoresis (PFGE) patterns and dendrogram of metallo-b-lactamase (MBL)-producing
Pseudomonas aeruginosa strains isolated from Aga Khan University Hospital during 2006–2007. The dendrogram was
constructed by cluster analysis using bionumerics software (version 3.5). Percentages of similarity are shown above the
dendrogram. The MBLA, MBLAR and MBLB isolates formed separate clusters, each with >80% similarity among the PFGE
profiles. The MBLAR isolates exhibited profiles >70% similar to those of the MBLA isolates, which indicates that both are
related, although the significance is unknown. CHR-01, CHR-02, CHR-03, CHR-04: VIM-2-producing P. aeruginosa from the
Calgary Health Region. AFC01–AFC15: VIM-2-producing P. aeruginosa from the Aga Khan University Hospital. AFC01,
AFC02, AFC03, AFC04, AFC05, AFC07, AFC08, AFC12, AFC13, AFC14 and AFC15 were isolated from the intensive-care
unit; AFC06, AFC09 AFC11 were isolated from general medical wards; and AFC10 was isolated from an outpatient.
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In summary, VIM-2-producing P. aeruginosa
was identified at a tertiary-care centre in Nairobi,
Kenya. A pan-resistant cluster was responsible for
several nosocomial outbreaks in the ICU of this
hospital, and continuous molecular surveillance is
required to monitor the spread of this cluster. This
study is the first report of VIM-2-producing
P. aeruginosa from the African continent.
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